Jennifer R. Cochran, Ph.D.

Stanford researchers have developed a new synthetic molecule, called PIP-CpG, that combines a tumor-targeting agent with a molecule that triggers immune activation. This treatment, can be administered intravenously and can make its way to multiple tumor sites, where it recruits immune cells against cancer.

Three doses of this new immunotherapy prolonged the survival of six of nine laboratory mice with an aggressive triple negative breast cancer. Of the six, three appeared cured of their cancer over the duration of the months long study. A single dose of this molecule induced complete tumor regression in five of ten mice. The synthetic molecule showed similar results in a mouse model of pancreatic cancer… Continue reading.

Scientists at Stanford and UC-San Francisco have developed an experimental drug that targets a currently untreatable type of lung cancer responsible for generating roughly 500,000 newly diagnosed cases worldwide each year.

A paper to be published online Nov. 7 in Nature Medicine reports that the researchers slowed the spread of this cancer in mice by neutralizing a single protein that would otherwise set off a chain reaction, causing runaway growth.

The paper is the result of a long-term collaboration between Stanford bioengineer Jennifer Cochran, Ph.D., and UCSF cancer researcher Alejandro Sweet-Cordero, MD… Continue reading.

WASHINGTON, D.C.—The American Institute for Medical and Biological Engineering (AIMBE) has announced the induction of Jennifer R. Cochran, Ph.D., Professor and Shriram Chair of Bioengineering, Professor, by courtesy, of Chemical Engineering, Bioengineering, Stanford University, to its College of Fellows. Dr. Cochran was nominated, reviewed, and elected by peers and members of the College of Fellows for fundamental advances in protein engineering, the development of tools for discovery, diagnosis and therapies, and for leadership in bioengineering.